

Cherevka Holli  
 Form 3  
 September 21, 2017

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2015  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Â Cherevka Holli (Last) (First) (Middle)	2. Date of Event Requiring Statement (Month/Day/Year) 09/19/2017	3. Issuer Name and Ticker or Trading Symbol Ampio Pharmaceuticals, Inc. [AMPE]	4. Relationship of Reporting Person(s) to Issuer  (Check all applicable)  <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other (give title below) (specify below) Chief Operating Officer	5. If Amendment, Date Original Filed(Month/Day/Year)
------------------------------------------------------------------------------------------	------------------------------------------------------------------------	-----------------------------------------------------------------------------------	-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	------------------------------------------------------

C/O AMPIO  
 PHARMACEUTICALS,  
 INC.,Â 373 INVERNESS  
 PARKWAY, SUITE 200  
 (Street)

ENGLEWOOD,Â COÂ 80112  
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
------------------------------------	----------------------------------------------------------	-------------------------------------------------------------------	----------------------------------------------------------

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative	5. Ownership Form of Derivative Security:	6. Nature of Indirect Beneficial Ownership (Instr. 5)
-----------------------------------------------	-------------------------------------------------------------	--------------------------------------------------------------------------------	-----------------------------------------------	-------------------------------------------	----------------------------------------------------------

Edgar Filing: Cherevka Holli - Form 3

	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Security	Direct (D) or Indirect (I) (Instr. 5)	
Stock Option (Right to Buy)	Â (1)	01/14/2023	Common Stock	35,000	\$ 4.16	D	Â
Stock Option (Right to Buy)	Â (2)	04/02/2023	Common Stock	45,000	\$ 4.72	D	Â
Stock Option (Right to Buy)	Â (3)	11/08/2023	Common Stock	80,000	\$ 8.62	D	Â
Stock Option (Right to Buy)	Â (4)	10/06/2024	Common Stock	30,000	\$ 3.43	D	Â
Stock Option (Right to Buy)	Â (5)	07/15/2026	Common Stock	170,000	\$ 1.03	D	Â
Stock Option (Right to Buy)	Â (6)	08/08/2026	Common Stock	30,000	\$ 0.51	D	Â
Stock Option (Right to Buy)	Â (7)	09/19/2027	Common Stock	200,000	\$ 0.55	D	Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Cherevka Holli C/O AMPIO PHARMACEUTICALS, INC. 373 INVERNESS PARKWAY, SUITE 200 ENGLEWOOD, CO 80112	Â	Â	Â Chief Operating Officer	Â

## Signatures

/s/ Holli  
Cherevka

09/21/2017

\*\*Signature of  
Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

The Stock Options vested and became exercisable in four installments. 1/4th of the options vested on the grant date of January 14, 2013,  
(1) 1/4 th of the options vested on January 14, 2014, 1/4th of the options vested on January 14, 2015 and 1/4th of the options vested on January 14, 2016.

The Stock Options vested and became exercisable in four installments. 1/4th of the options vested on the grant date of April 2, 2013, 1/4  
(2) th of the options vested on January 14, 2014, 1/4th of the options vested on January 14, 2015 and 1/4th of the options vested on January 14, 2016.

(3) The Stock Options vested and became exercisable monthly over 36 months in equal installments.

(4) The Stock Options vested and became exercisable in two installments. 1/2 of the options vested on the grant date of October 6, 2014, and 1/2th of the options vested on October 6, 2015.

### Edgar Filing: Cherevka Holli - Form 3

- (5) The Stock Options vest and become exercisable in three installments. 1/3rd of the options vested on the grant date of July 15, 2016, 1/3rd of the options vested on July 15, 2017 and 1/3rd of the options vest on July 15, 2018.
- (6) The Stock Options vest and become exercisable immediately.
- (7) The Stock Options vest and become exercisable in two equal installments. 1/2 of the options vested on the grant date of September 19, 2017; and the additional 1/2 of the options shall vest on September 19, 2018.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.